We are live on ! Find out more
MRKR icon

Marker Therapeutics

65 hedge funds and large institutions have $44.5M invested in Marker Therapeutics in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 15

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.37% less ownership

Funds ownership: 3.75%3.38% (-0.37%)

11% less funds holding

Funds holding: 7365 (-8)

23% less call options, than puts

Call options by funds: $160K | Put options by funds: $208K

44% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 18

49% less capital invested

Capital invested by funds: $87.6M → $44.5M (-$43.1M)

Holders
65
Holders Change
-8
Holders Change %
-10.96%
% of All Funds
1.28%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
22
Reduced
15
Closed
18
Calls
$160K
Puts
$208K
Net Calls
-$48K
Net Calls Change
-$420K

MRKR Hedge Fund Activity: Q4 2019 in Review

65 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2019, worth a combined $44.5M — down 49% from $87.6M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of MRKR and 10 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 22 added.

The largest buyer was GSA Capital Partners, opening a new position worth an estimated $609K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $10.2M sold.

  • 65 institutional investors held Marker Therapeutics (MRKR) as of Q4 2019, down from 73 in Q3 2019.
  • Funds reported $44.5M of Marker Therapeutics stock for Q4 2019, down 49% quarter-over-quarter.
  • 10 funds opened new Marker Therapeutics positions in Q4 2019 and 18 closed out, a net change of -8 holders.
  • The largest Marker Therapeutics buyer in Q4 2019 was GSA Capital Partners, an estimated $609K added.
  • The largest Marker Therapeutics seller in Q4 2019 was Perceptive Advisors, an estimated $10.2M sold.

Based on aggregated 13F filings for Q4 2019.